Renal Cancer - Results from #720

Systemic Inflammatory Biomarkers Predict Survival of Patients Treated With Tyrosine Kinase Inhibitors for Metastatic Renal Cell Carcinoma. September 27, 2023

PERK Inhibition by HC-5404 Sensitizes Renal Cell Carcinoma Tumor Models to Antiangiogenic Tyrosine Kinase Inhibitors. September 26, 2023

Integrating Red Blood Cell Features and Hemoglobin Levels in Metastatic Renal Cell Carcinoma Patients Treated with Pazopanib or Cabozantinib: An Easily Exploitable Prognostic Score. September 26, 2023

Serum concentrations of per- and polyfluoroalkyl substances and risk of renal cell carcinoma in the Multiethnic Cohort Study. September 26, 2023

A new scaffold-free tumoroid model provides a robust preclinical tool to investigate invasion and drug response in Renal Cell Carcinoma. September 25, 2023

Preoperative prognostic model for localized and locally advanced renal cell carcinoma: Michinoku Japan Urological Cancer Study Group. September 25, 2023

Prognostic significance of MALAT1 in clear cell renal cell carcinoma based on TCGA and GEO. September 22, 2023

Can Simplified PADUA Renal (SPARE) Nephrometry scoring system help predict renal function outcomes after robot-assisted partial nephrectomy? (UroCCR study 93). September 22, 2023

Spatially aware deep learning reveals tumor heterogeneity patterns that encode distinct kidney cancer states. September 22, 2023

Construction of the metabolic reprogramming-associated gene signature for clear cell renal cell carcinoma prognosis prediction. September 21, 2023

Fatty acid metabolism-related genes as a novel module biomarker for kidney renal clear cell carcinoma: Bioinformatics modeling with experimental verification. September 21, 2023

Association between age and efficacy of first-line immunotherapy-based combination therapies for mRCC: a meta-analysis. September 20, 2023

Real-world clinical outcomes of patients with metastatic renal cell carcinoma receiving pembrolizumab + axitinib vs. ipilimumab + nivolumab. September 20, 2023

FDA Accepts for Priority Review Merck’s Supplemental New Drug Application for WELIREG® (belzutifan) in Certain Previously Treated Patients With Advanced Renal Cell Carcinoma (RCC) September 19, 2023

Complications after partial nephrectomy: robotics overcomes open surgery and laparoscopy: the PMSI French national database. September 19, 2023

Efficacy and safety of cabozantinib rechallenge in metastatic renal cell carcinoma: A retrospective multicentric study. September 19, 2023

Establishment of a new prognostic risk model of GNG7 pathway-related molecules in clear cell renal cell carcinoma based on immunomodulators. September 18, 2023

Socioeconomic determinants of racial disparities in survival outcomes among patients with renal cell carcinoma. September 18, 2023

Early kinetics of C-reactive protein as prognosticator for survival in a real-world cohort of patients with metastatic renal cell cancer under first-line therapy with immune checkpoint inhibitors. September 15, 2023

A comprehensive analysis of MYO6 as a promising biomarker for diagnosis, prognosis, and immunity in clear cell renal cell carcinoma. September 15, 2023

Page 37 of 456